In the past 12 months, 11 drug companies reported profit margins exceeding 25 percent, meaning they kept 25 cents of every dollar brought in after operating costs. Mylan, the Amsterdam-based maker of EpiPens, posted a 20 percent profit margin.
USA Today analyzed drugmakers’ profit margins using data from S&P GlobalMarket Intelligence.
Here are the 11 drugmakers with the highest operating profit margins.
- Gilead Sciences (Foster City, Calif.) — 62.7 percent
- Biogen (Cambridge, Mass.) — 49.3 percent
- Amgen (Thousand Oaks, Calif.) — 41.5 percent
- Abbvie (North Chicago, Ill.) —38.9 percent
- Celgene (Summit, N.J.) — 32.3 percent
- Zoetis (Florham Park, N.J.) — 28.1 percent*
- Pfizer (New York City) — 27.8 percent
- Bristol-Myers Squibb (New York City) — 27.3 percent
- Johnson & Johnson (New Brunswick, N.J.) — 27.2 percent
- Regeneron (Tarrytown, N.Y.) — 26.8 percent
- Alexion (Cheshire, Conn.) — 25.3 percent
*Zoetis is a global animal health company.
More articles on supply chain:
EpiPens no longer free for South Carolina’s largest school district
Supply chain tip of the week: How to engage physicians in the decision-making process
Mylan vows to reduce patient costs in light of EpiPen pricing scandal
